Search Results for “antibody” – Page 68 – media

BioNTech raises $270M A round to fuel mRNA, CAR-T R&D

BioNTech has raised $270 million (€224 million). The series A round positions the German biotech to mount a multifront attack on cancer, spearheaded by mRNA therapies and supported by a clutch of other modalities including CAR-T cells.
- Source: fiercebiotech
- 644
- January 5, 2018
CAR-T therapy Company Insight mRNA Series
Triple drug treatment combo shows promise in adult leukemia

A triple-drug focused remedy method may provide an efficient new treatment choice for power lymphocytic leukemia (CLL) that reduces the chance for the lengthy-time period unintended effects skilled with chemotherapy and is given for a restricted time, not as a day by day lifetime drug remedy.
- Source: medical-newspaper
- 579
- December 21, 2017
Chemotherapy diabetes Researches triple-drug
FDA Accepts Biologics License Application for Fremanezumab with Priority Review for Prevention of Migraine and Grants Fast Track Designation for Cluster Headache Development Program

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) for fremanezumab, an anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibody for the preventive treatment of migraine. Additionally, the FDA has granted fast track designation for fremanezumab for the prevention of cluster headache.
- Source: finance.yahoo
- 570
- December 19, 2017
cluster headache FDA fremanezumab migraine New Approvals Teva
FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome

The U.S. Food and Drug Administration(FDA) expanded the approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, an inflammation in the wall of blood vessels of the body. This new indication provides the first FDA-approved therapy specifically to treat EGPA.
- Source: Prnewswire;
- 489
- December 14, 2017
EGPA New Approvals vasculitis
Lilly’s Taltz cleared to treat psoriatic arthritis

US regulators have expanded the scope of Eli Lilly’s plaque psoriasis drug Taltz to include the treatment patients with psoriatic arthritis.
- Source: Pharmatimes
- 486
- December 6, 2017
New Approvals plaque psoriasis Taltz
New Drugs Could Prevent Migraine Headaches For Some People

People who experience frequent migraines may soon have access to a new class of drugs. In a pair of large studies, two drugs that tweak brain circuits involved in migraine each showed they could reduce the frequency of attacks without causing side effects, researchers report in the New England Journal of Medicine.
- Source: npr
- 513
- December 5, 2017
brain drug epilepsy Researches
Is Mepolizumab an Effective Treatment for Asthma?

Researchers investigated whether mepolizumab is safer and more effective than triple-inhaled treatments for chronic obstructive pulmonary disease.
- Source: medicalnewsbulletin
- 670
- December 4, 2017
asthma COPD mepolizumab
Kyowa Hakko Kirin Announces FDA Acceptance for Filing and Priority

Review Designation of Mogamulizumab’s Biologics License Application
- Source: drugdu
- 482
- November 29, 2017
Biologics License Application FDA New Approvals
FDA OKs Genentech’s Gazyva for Untreated Follicular Lymphoma

Twice on Thursday, Genentech, scored two approvals from the U.S. Food and Drug Administration(FDA) – a new medicine for hemophilia and an expansion for its cancer drug Gazyva.
- Source: Biospace
- 595
- November 21, 2017
cancer FDA hemophilia lymphoma New Approvals
FDA approves new treatment Hemlibra (emicizumab-kxwh) to prevent bleeding in certain patients with hemophilia A

The U.S. Food and Drug Administration(FDA) approved Hemlibra (emicizumab-kxwh) to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors.
- Source: pharmacist
- 744
- November 20, 2017
FDA Hemlibra hemophilia inhibitor New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.